Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

NCT05561374 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

High-grade Glioma
Oligodendroglioma
Astrocytoma
Glioblastoma Multiforme

Interventions

DRUG: Low-dose OKN-007, BID
DRUG: Low-dose OKN-007, TID
DRUG: Mid-dose OKN-007, TID
DRUG: High-dose OKN-007, TID

Sponsor

Oblato, Inc.